(Q38062881)

28 August 2017

1 reference

title

Linagliptin/Metformin fixed-dose combination treatment: a dual attack to type 2 diabetes pathophysiology (English)

1 reference

28 August 2017

1 reference

1 reference

Chrysi Koliaki

1

1 reference

28 August 2017

John Doupis

series ordinal

2

1 reference

28 August 2017

language of work or name

English

0 references

publication date

23 November 2012

1 reference

28 August 2017

1 reference

28 August 2017

volume

29

1 reference

28 August 2017

issue

12

1 reference

28 August 2017

page(s)

993-1004

1 reference

https://scigraph.springernature.com/pub.10.1007/s12325-012-0067-z

28 August 2017

exact match

0 references

cites work

Oral antihyperglycemic therapy for type 2 diabetes: scientific review

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0067-Z

Prevalence of inadequate glycemic control among patients with type 2 diabetes in the United Kingdom general practice research database: A series of retrospective analyses of data from 1998 through 2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0067-Z

DPP4 inhibitors: a new approach in diabetes treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0067-Z

Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0067-Z

Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0067-Z

Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0067-Z

Linagliptin: the newest dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0067-Z

Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0067-Z

Linagliptin: a review of its use in the management of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0067-Z

Biology of incretins: GLP-1 and GIP

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0067-Z

Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0067-Z

Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0067-Z

Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0067-Z

Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0067-Z

Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0067-Z

Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0067-Z

The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves β-cell mass in non-obese diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0067-Z

The effect of linagliptin on glycaemic control and tolerability in patients with type 2 diabetes mellitus: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0067-Z

Pharmacokinetics of linagliptin in subjects with hepatic impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0067-Z

Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0067-Z

Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0067-Z

(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared wi

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0067-Z

Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0067-Z

Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0067-Z

Sulfonylureas or dipeptidyl peptidase (DPP-4) inhibitors in the management of type 2 diabetes: debate is not yet closed.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0067-Z

Incretin-based therapies and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0067-Z

Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0067-Z

Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0067-Z

Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0067-Z

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0067-Z

Role of AMP-activated protein kinase in mechanism of metformin action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0067-Z

Metformin Inhibits Hepatic Gluconeogenesis Through AMP-Activated Protein Kinase-Dependent Regulation of the Orphan Nuclear Receptor SHP

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0067-Z

Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0067-Z

Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0067-Z

Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0067-Z

Clinical pharmacokinetics and pharmacodynamics of linagliptin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0067-Z

Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0067-Z

Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0067-Z

Sulfonylurea Compounds Uncouple the Glucose Dependence of the Insulinotropic Effect of Glucagon-Like Peptide 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0067-Z

10.1007/S12325-012-0067-Z

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

1020772767

0 references

1 reference